Jaan Biotherapeutics, LLC is a private company using proprietary technology to develop novel therapies to activate the cardiac regeneration process in diseased hearts. The technology manipulates microRNAs to activate an endogenous cardiac muscle regeneration process which has been shut down in the adult human heart during evolution. JBT's is developing a cardiac muscle regeneration therapy currently focused on ischemic heart disease. The therapy, based on a Salk institute patent with UCSD confirming studies, inhibits 4 miRs to activate the endogenous cardiac muscle regeneration process suppressed in adult humans in the evolution process.
